Estrogen receptor modulator raw material Raloxifene Hydrochloride

Min.Order / FOB Price:Get Latest Price

1 Gram	FOB Price: USD 50.0000

1 Gram

FOB Price: USD 50.0000

Min.Order :1 Gram
Purity: 99
Payment Terms : T/T,,MoneyGram

Keywords

Raloxifene Hydrochloride Testosterone Base Testosterone Acetate

Quick Details

Appearance:Light Yellow Powde
Application:English name: Raloxifene hydrochloride English Synonyms: Raloxifene hydrochloride; Evista; Keoxifene hydrochloride; LY 156758; Raloxifene HCl;
PackAge:Foil bag
ProductionCapacity:50000|Kilogram|Week
Storage:Placed in a cool place
Transportation:

Superiority:

Raloxifene Hydrochloride

Product Name Raloxifene HCl Powder

CAS Registry Number 82640-04-8

Molecular Formula C28H28ClNO4S

Molecular Weight 510.05

Purity 99%

Grade Pharmaceutical Grade

Appearance Light Yellow Powde

Details:

Raloxifene Hydrochloride

Product Name Raloxifene HCl Powder

CAS Registry Number 82640-04-8

Molecular Formula C28H28ClNO4S

Molecular Weight 510.05

Purity 99%

Grade Pharmaceutical Grade

Appearance Light Yellow Powde

1. Quick Detail:

Anti Estrogen Steroids Raloxifene Hydrochloride CAS 82640-04-8 Raloxifene HCL for Anti Cancer

2. Description:

English name: Raloxifene hydrochloride

English Synonyms: Raloxifene hydrochloride; Evista; Keoxifene hydrochloride; LY 156758; Raloxifene HCl;

CAS: 82640-04-8

Formula: C28H29NO4S

MW: 475.5992

Molecular Structure:

Density: 1.285g / cm3

Boiling point: 687.5 ° C at 760 mmHg

Flash Point: 369.6 ° C

Vapor Pressure: 1.56E-19mmHg at 25 ° C

Assay:99%

Appearance:light yellow powder

Use:antineoplastic

3. Applications:

May prevent or treat corticosteroid-induced bone loss .American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents (e.g., bisphosphonates, calcitonin) or in whom such therapies are contraindicated.

Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis.

Reduction in the incidence of invasive breast cancer in postmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial).No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial).Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established.

View All

Visit Store